| __timestamp | Novartis AG | Soleno Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 9086000000 | 2242216 |
| Thursday, January 1, 2015 | 8935000000 | 4536244 |
| Friday, January 1, 2016 | 9039000000 | 5184803 |
| Sunday, January 1, 2017 | 8972000000 | 3068742 |
| Monday, January 1, 2018 | 9074000000 | 7178000 |
| Tuesday, January 1, 2019 | 9402000000 | 16267000 |
| Wednesday, January 1, 2020 | 8980000000 | 23191000 |
| Friday, January 1, 2021 | 9540000000 | 21453000 |
| Saturday, January 1, 2022 | 9996000000 | 15265000 |
| Sunday, January 1, 2023 | 11371000000 | 25189000 |
| Monday, January 1, 2024 | 10022000000 |
Unlocking the unknown
In the ever-evolving pharmaceutical landscape, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Novartis AG and Soleno Therapeutics, Inc. have demonstrated contrasting approaches to R&D investment.
From 2014 to 2023, Novartis AG consistently allocated substantial resources to R&D, with expenditures peaking at approximately $11.4 billion in 2023, marking a 25% increase from 2014. This robust investment underscores Novartis's dedication to maintaining its competitive edge in the global market.
Conversely, Soleno Therapeutics, Inc., a smaller player, exhibited a more modest R&D budget, with a notable increase from $2.2 million in 2014 to $25.2 million in 2023. This tenfold growth reflects Soleno's strategic focus on niche therapeutic areas.
These divergent strategies highlight the varied paths companies take in the pursuit of medical breakthroughs, each tailored to their unique market positions and goals.
Who Prioritizes Innovation? R&D Spending Compared for Johnson & Johnson and Novartis AG
Novartis AG vs Protagonist Therapeutics, Inc.: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for Novartis AG and MorphoSys AG
Research and Development Expenses Breakdown: Alnylam Pharmaceuticals, Inc. vs Soleno Therapeutics, Inc.
Comparing Innovation Spending: Insmed Incorporated and Soleno Therapeutics, Inc.
R&D Insights: How Bio-Techne Corporation and Soleno Therapeutics, Inc. Allocate Funds
Ultragenyx Pharmaceutical Inc. or Soleno Therapeutics, Inc.: Who Invests More in Innovation?
Analyzing R&D Budgets: Veracyte, Inc. vs Soleno Therapeutics, Inc.
Research and Development Expenses Breakdown: Bausch Health Companies Inc. vs Soleno Therapeutics, Inc.
Research and Development Expenses Breakdown: ImmunityBio, Inc. vs Soleno Therapeutics, Inc.
Soleno Therapeutics, Inc. or MannKind Corporation: Who Invests More in Innovation?
Who Prioritizes Innovation? R&D Spending Compared for Soleno Therapeutics, Inc. and Dynavax Technologies Corporation